| Marcia Liss, PHD | |
|
1351 S County Trl, Building 2 Suite 210, East Greenwich, RI 02818-5079 | |
| (401) 884-2088 | |
| (401) 884-2075 |
| Full Name | Marcia Liss |
|---|---|
| Gender | Female |
| Speciality | Clinical Psychologist |
| Experience | 33 Years |
| Location | 1351 S County Trl, East Greenwich, Rhode Island |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922039353 | NPI | - | NPPES |
| COORDINATED HEALTH P | Other | RI | 407788 |
| 30027-8 | Other | RI | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | PS00692 (Rhode Island) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lifespan Physician Group Inc | 2567455082 | 631 |
News Archive
Cell Therapeutics, Inc. today announced that The NASDAQ Stock Market has granted CTI an additional 180 days to regain compliance with NASDAQ's $1.00 minimum bid price rule under NASDAQ Marketplace Rule 5550(a)(2)). Previously, on May 3, 2010, CTI was notified by NASDAQ that CTI did not meet the minimum bid price rule required for continued listing and was provided until November 1, 2010 to achieve compliance.
Working with human breast cancer cells and mice, researchers at Johns Hopkins say they have identified a biochemical pathway that triggers the regrowth of breast cancer stem cells after chemotherapy.
Eyetech Pharmaceuticals and Pfizer have announced that the U.S. Food and Drug Administration (FDA) approved Macugen (pegaptanib sodium injection) for the treatment of neovascular (wet) age-related macular degeneration (AMD), an eye disease associated with aging that destroys central vision.
FoodMinds, a food and nutrition company that harnesses science, public affairs and communications, is rolling into 2010 with new client partnerships and an expanding roster of full-time team members.
› Verified 2 days ago
| Entity Name | Lifespan Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548506793 PECOS PAC ID: 2567455082 Enrollment ID: O20130528000089 |
News Archive
Cell Therapeutics, Inc. today announced that The NASDAQ Stock Market has granted CTI an additional 180 days to regain compliance with NASDAQ's $1.00 minimum bid price rule under NASDAQ Marketplace Rule 5550(a)(2)). Previously, on May 3, 2010, CTI was notified by NASDAQ that CTI did not meet the minimum bid price rule required for continued listing and was provided until November 1, 2010 to achieve compliance.
Working with human breast cancer cells and mice, researchers at Johns Hopkins say they have identified a biochemical pathway that triggers the regrowth of breast cancer stem cells after chemotherapy.
Eyetech Pharmaceuticals and Pfizer have announced that the U.S. Food and Drug Administration (FDA) approved Macugen (pegaptanib sodium injection) for the treatment of neovascular (wet) age-related macular degeneration (AMD), an eye disease associated with aging that destroys central vision.
FoodMinds, a food and nutrition company that harnesses science, public affairs and communications, is rolling into 2010 with new client partnerships and an expanding roster of full-time team members.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marcia Liss, PHD 1351 S County Trl, Building 2 Suite 210, East Greenwich, RI 02818-5079 Ph: (401) 884-2088 | Marcia Liss, PHD 1351 S County Trl, Building 2 Suite 210, East Greenwich, RI 02818-5079 Ph: (401) 884-2088 |
News Archive
Cell Therapeutics, Inc. today announced that The NASDAQ Stock Market has granted CTI an additional 180 days to regain compliance with NASDAQ's $1.00 minimum bid price rule under NASDAQ Marketplace Rule 5550(a)(2)). Previously, on May 3, 2010, CTI was notified by NASDAQ that CTI did not meet the minimum bid price rule required for continued listing and was provided until November 1, 2010 to achieve compliance.
Working with human breast cancer cells and mice, researchers at Johns Hopkins say they have identified a biochemical pathway that triggers the regrowth of breast cancer stem cells after chemotherapy.
Eyetech Pharmaceuticals and Pfizer have announced that the U.S. Food and Drug Administration (FDA) approved Macugen (pegaptanib sodium injection) for the treatment of neovascular (wet) age-related macular degeneration (AMD), an eye disease associated with aging that destroys central vision.
FoodMinds, a food and nutrition company that harnesses science, public affairs and communications, is rolling into 2010 with new client partnerships and an expanding roster of full-time team members.
› Verified 2 days ago
Dr. Jonathan K Lee, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1454 S County Trl, Suite 2200, East Greenwich, RI 02818 Phone: 401-606-4415 Fax: 401-606-1146 | |
Dr. Gerald P Champagne, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 126 Peirce St, East Greenwich, RI 02818 Phone: 401-885-5677 Fax: 401-886-0693 | |
Dr. William Paul Macaux, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 169 Spencer Ave, East Greenwich, RI 02818 Phone: 401-885-1631 | |
Dr. Concetta Mary Di Leonardo, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1351 S County Trl, Building 2--suite 210, East Greenwich, RI 02818 Phone: 401-884-2008 Fax: 401-884-2075 | |
Kristen Peters Bierwirth, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1485 S County Trl Ste 107, East Greenwich, RI 02818 Phone: 401-733-3349 Fax: 401-941-7847 | |
Dr. Judith A Scarfpin, EDD IN PSYCHOLOGY Psychologist Medicare: Not Enrolled in Medicare Practice Location: 688 Frenchtown Rd, #4, East Greenwich, RI 02818 Phone: 401-885-6772 | |
Katarina Lukatela, PH D Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1351 S County Trl, Building 2, East Greenwich, RI 02818 Phone: 401-884-2008 Fax: 401-884-2075 |